Blueprint Medicines Corporation

Early development of CDK2 inhibitors has been beset with tolerability problems, particularly ocular and hematological, but new data for two products suggest that headway is being made for some candida

IDRx, Inc is hoping to use its latest round of venture capital funding to advance its drug IDRX-42 to tackle a sarcoma subtype, gastrointestinal stromal tumor (GIST), that remains underserved despite

Experts in expanded access programs gave a glimpse of the difficulties in getting investigational drugs to patients, from helping physicians navigate the process to budgeting funds to pay for the prog

Fewer investment dollars are going to oncology-focused and platform technology companies, but there has been an uptick in investment in disease areas – even at the preclinical stage – that just a few